Overview

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Phase:
Phase 2
Details
Lead Sponsor:
Loren Mell, MD
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab